This page shows you your search results in order of date. This is page number 20.

Order by Relevance | Date

Total 12496 results found since Jan 2013.

Buprenorphine/naloxone/paracetamol
Source: Reactions Weekly - August 1, 2023 Category: Drugs & Pharmacology Source Type: research

BUPRENORPHINE tablet Rhodes Pharmaceuticals L.P.
Updated Date: Mon, 31 Jul 2023 00:00:00 EDT
Source: DailyMed Drug Label Updates - July 31, 2023 Category: Drugs & Pharmacology Source Type: alerts

Efficacy and safety of tramadol in the treatment of opioid withdrawal: A meta-analysis of randomized controlled trials
CONCLUSION: Authors conclude that the efficacy of tramadol in reducing opioid withdrawal symptoms is not significantly different from comparators with low certainty of evidence against placebo, moderate against methadone, whereas with high certainty of evidence against buprenorphine and clonidine.PMID:37517376 | DOI:10.1016/j.addbeh.2023.107815
Source: Addictive Behaviors - July 30, 2023 Category: Addiction Authors: Milan Padhan Rituparna Maiti Debadatta Mohapatra Biswa Ranjan Mishra Source Type: research

Molecules, Vol. 28, Pages 5766: Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain
ika Neuropathic pain is a debilitating condition that affects millions of people worldwide. Numerous studies indicate that this type of pain is a chronic condition with a complex mechanism that tends to worsen over time, leading to a significant deterioration in patients’ quality of life and issues like depression, disability, and disturbed sleep. Presently used analgesics are not effective enough in neuropathy treatment and may cause many side effects due to the high doses needed. In recent years, many researchers have pointed to the important role of chemokines not only in the development and maintenanc...
Source: Molecules - July 30, 2023 Category: Chemistry Authors: Katarzyna Pawlik Joanna Mika Tags: Review Source Type: research

Remote Urine Drug Screening Feasible for Opioid Use Disorder, Study Shows
(MedPage Today) -- Remotely administered urine drug screening was found to be feasible in patients with opioid use disorder (OUD) who were receiving buprenorphine in remote care settings, according to a cohort study. Of more than 3,000 patients...
Source: MedPage Today Psychiatry - July 28, 2023 Category: Psychiatry Source Type: news

Urine Drug Screens as Part of OUD Treatment Can Be Successfully Managed Via Telehealth
Urine drug screening of people in treatment for opioid use disorder (OUD) is feasible and reliable via telehealth, according to a studypublished today inJAMA Health Forum.“This cohort study’s findings … are consistent with the premise that long-standing and stringent requirements (e.g., requiring in-person visits, frequent drug testing) for being prescribed buprenorphine for OUD can be relaxed without jeopardizing the quality or safety of care for many patients ,” wrote Arthur Robin Williams, M.D., M.B.E., of Columbia University and colleagues. Williams is also chief medical officer of Ophelia, a telehealth-based O...
Source: Psychiatr News - July 28, 2023 Category: Psychiatry Tags: Arthur Robin Williams buprenorphine Ophelia opioid use disorder OUD treatment telehealth urine drug screening urine test Source Type: research

Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers
Conclusion: NJ policies may have improved access to care for Medicaid beneficiaries by reducing barriers to care and supporting providers in prescribing MOUD. Yet, stigma and lack of psychosocial supports still need to be addressed to further improve access and care quality.PMID:37506336 | DOI:10.1080/00952990.2023.2234075
Source: The American Journal of Drug and Alcohol Abuse - July 28, 2023 Category: Addiction Authors: Anais Mahone Michael Enich Peter Treitler James Lloyd Stephen Crystal Source Type: research

Early Emergency Department Experience with 7-day Extended-Release Injectable Buprenorphine for Opioid Use Disorder
We report our early experiences with this medication, (investigational drug CAM2038) in the context of an ongoing clinical trial entitled, Emergency Department-Initiated BUP VAlidaTION (ED INNOVATION), to inform emergency clinicians as they consider incorporating this medication into their practice. The medication was approved by the European Medicines Agency in 2018 and the U.S. Food and Drug Administration in 2023 for those 18 years or older for the treatment of moderate to severe opioid use disorder (OUD). We report our experience with approximately 800 ED patients with opioid use disorder (OUD) who received the 7-day X...
Source: Accident and Emergency Nursing - July 28, 2023 Category: Emergency Medicine Authors: Gail D'Onofrio Jeanmarie Perrone Kathryn F Hawk Ethan Cowan Ryan McCormack Edouard Coupet Patricia H Owens Shara H Martel Kristen Huntley Sharon L Walsh Michelle R Lofwall Andrew Herring ED-INNOVATION Investigators Source Type: research

Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers
Conclusion: NJ policies may have improved access to care for Medicaid beneficiaries by reducing barriers to care and supporting providers in prescribing MOUD. Yet, stigma and lack of psychosocial supports still need to be addressed to further improve access and care quality.PMID:37506336 | DOI:10.1080/00952990.2023.2234075
Source: The American Journal of Drug and Alcohol Abuse - July 28, 2023 Category: Addiction Authors: Anais Mahone Michael Enich Peter Treitler James Lloyd Stephen Crystal Source Type: research